Portal de Periódicos da CAPES

Artigo Produção Nacional Revisado por pares

BIBTEX RIS

Exploratory study of humoral and cellular immunity to 17DD Yellow Fever vaccination in children and adults residents of areas without circulation of Yellow Fever Virus

2021; Elsevier BV; Volume: 40; Issue: 5 Linguagem: Inglês

10.1016/j.vaccine.2021.12.029

1873-2518

Laise Rodrigues Reis, Ismael Artur da Costa-Rocha, Ana Carolina Campi‐Azevedo, Vanessa Peruhype-Magalhães, Jordana Grazziela Coelho-dos-Reis, Christiane Costa-Pereira, Dayane Andriotti Otta, Larissa Chaves Freire, Sheila Maria Barbosa de Lima, Adriana de Souza Azevedo, Waleska Dias Schwarcz, Ana Paula Dinis Ano Bom, Andréa Marques Vieira da Silva, Alessandro Fonseca de Souza, Thalita da Matta de Castro, Clara Lucy de Vasconcellos Ferroco, Ana María Bispo de Filippis, Fernanda de Bruycker Nogueira, Akira Homma, Carla Magda Allan Santos Domingues, Eduardo Sérgio Soares Sousa, Luiz Antônio Bastos Camacho, Maria de Lourdes Maia, Andréa Teixeira−Carvalho, Olindo Assis Martins‐Filho,

Vibrio bacteria research studies

The present investigation comprised two independent observational arms to evaluate the influence of pre-existing flavivirus humoral immunity and the age-impact on 17DD-YF vaccination immunity. Flavivirus (YFV; DENV; ZIKV) serology and YF-specific cellular immunity was evaluated in 288 children/9Mths–4Yrs and 288 adults/18–49Yrs residents of areas without YFV circulation. Data demonstrated that flavivirus seropositivity at baseline was higher in Adults as compared to Children (26%;87%;67% vs 6%;13%;15%, respectively). The heterologous flavivirus seropositivity (DENV; ZIKV) did not impact the YF-specific cellular immune response at baseline. However, higher levels of NCD4, EMCD8, IFN-MCD8, NCD19 and nCMCD19 were observed in subjects with pre-existing YFV seropositivity. Primary vaccination of YFV-seronegative volunteers led to higher levels of YF-neutralizing antibodies in Adults as compared to Younger Children (9Mths–2Yrs). Although similar seropositivity rates observed amongst Children and Adults at D30-45, lower rates were observed in Younger Children (9Mths–2Yrs) at D365 (94%;95%;100% vs 87%;96%;99%, respectively). A progressive decline in antibody levels were reported at D365, being more expressive in Children as compared to Adults. All age-subgroups exhibited at D30-45 increased levels of eEfCD4, EMCD4, IFN-MCD8 and nCMCD19 together with a decrease of eEfCD8 and CMCD8. While an increase of EMCD8 were observed in all subgroups at D30-45, a declined duration at D365 was reported only in Younger Children (9Mths–2Yrs). Biomarker signatures further support that only Younger Children (9Mths–2Yrs) presented a progressive decline of EMCD8 at D365. Together, these findings demonstrated that regardless the similarities observed in YF-neutralizing antibodies, the age impacts the duration of cellular immune response to primary 17DD-YF vaccination.